Target intelligence / Profile preview

Serine protease 1 (Trypsin-1) (PRSS1)

Target
PRSS1
Molecular classification
Enzyme, Serine protease
01

Overview

Human trypsin-1, also known as cationic trypsinogen and encoded by the PRSS1 gene, is the most abundant isoform of trypsinogen produced by the pancreatic acinar cells [1, 10]. It is secreted into the duodenum as an inactive zymogen and subsequently activated by enteropeptidase, where it plays a central role in digestion by cleaving proteins at lysine and arginine residues [2, 12]. Beyond its direct digestive function, trypsin-1 is responsible for the proteolytic activation of other pancreatic zymogens, including chymotrypsinogen and procarboxypeptidases [2, 11]. Mutations in the PRSS1 gene, particularly gain-of-function variants like R122H, are strongly associated with hereditary pancreatitis due to premature activation of the enzyme within the pancreas, leading to autodigestion and chronic inflammation [3, 12]. Consequently, trypsin-1 is a significant therapeutic target; serine protease inhibitors such as camostat and nafamostat are employed to mitigate its activity in inflammatory pancreatic conditions [5, 13]. Additionally, its involvement in activating protease-activated receptors (PARs) suggests a broader role in signaling pathways related to cancer progression and pain [15, 17]. The enzyme's activity is naturally regulated by inhibitors like SPINK1, and imbalances in this protease-antiprotease system are central to pancreatic pathology [4, 14]. Monitoring trypsin-1 levels or its activation peptides serves as a critical biomarker for diagnosing pancreatic disorders and assessing disease severity [17, 18].

Other names
Cationic trypsinogenTrypsinogen 1TRY1TRP1TRYP1Protease, serine 1Beta-trypsin
02

Mechanism of action

Serine protease inhibition

03

Biological functions

DigestionProteolysisZymogen activation
04

Disease associations

PancreatitisCancerInflammationTrypsinogen deficiency
05

Safety considerations

Selectivity between trypsin isoformsSystemic protease inhibitionGastrointestinal side effects
06

Interacting drugs

Camostat

4 more in the full profile.

07

Biomarkers

Serum trypsinogen (Immunoreactive trypsinogen)Trypsin-activated peptide (TAP)PRSS1 mutation status

Beyond the preview

Go deeper on Serine protease 1 (Trypsin-1) (PRSS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Serine protease 1 (Trypsin-1) (PRSS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call